Fig. 3: Pharmacokinetic and pharmacodynamic properties of PROTAC 4 in rats.
From: Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
a Combined plot showing the relative time profiles for the pharmacokinetics and corresponding pharmacodynamics for PROTAC 4 after SC dosing at 20 mg/kg. b RIPK2 levels over time compared to individual animal pre-dose levels after SC dosing at 1, 5 and 20 mg/kg. c Rat exposure profiles for PROTAC 4. Data points are shown as mean ± s.e.m. (n = 5).
